专家介绍

刘静博士，中科院合肥物质科学研究院健康与医学技术研究所研究员，博士生导师。2001年获南开大学化学学士学位，2008年于美国Texas A&M大学获得化学博士学位，2009-2013年间先后在美国Texas A&M大学化学系与美国哈佛大学医学院细胞生物学系从事博士后研究，2013年加入中国科学院强磁场科学中心任研究员，2020年加入健康与医学技术研究所任研究员。2015年入选国家高层次人才计划。刘静研究员主要通过药物化学、化学生物学等研究方法发展新型小分子抑制剂和分子探针，开展与重大疾病特别是癌症相关的分子机制研究以及新型诊断试剂的开发。近年来依托中科院合肥研究院的药物学研究平台，着重发展新型针对癌症分子分型的小分子抑制剂并探究相关肿瘤病理机制，围绕肿瘤精准靶向治疗新策略开展药物化学等方面的研究。迄今已在Cell、Nat Chem Biol、PNAS（Nature Methods亮点点评）, Leukemia、J Med Chem等国际期刊上发表SCI论文50余篇，参与编写国际专著2部。获得中国授权专利10余项，美国授权专利6项，申请中国及PCT专利40余项。所研发的一种针对急性白血病的化药1类新药获得国家临床试验批件。此外，所发展的新型激酶抑制剂中有10个作为科研用工具分子目前在市场上进行销售。

1) Selectively Targeting FLT3-ITD Mutants Over FLT3-wt by a Novel Inhibitor for Acute Myeloid Leukemia - Haematologica - 202004 - 2021, 106(2):605-609.
2) Discovery of a highly potent and selective Bruton’s tyrosine kinase inhibitor avoiding impairment of ADCC effects for B-cell non-Hodgkin lymphoma - Signal Transduction and Targeted Therapy - 202009 - 2020, 5(1):200.
3) All-trans retinoic acid exerts selective anti-FLT3-ITD acute myeloid leukemia efficacy through downregulating Chk1 kinase - Cancer Letters - 202003 - 2020, 473:130-138.
4) Repurposing cabozantinib to GISTs: Overcoming multiple imatinib-resistant cKIT mutations including gatekeeper and activation loop mutants in GISTs preclinical models - Cancer Letters - 201901 - 2019, 447:105-114.
5) Discovery of a highly potent FLT3 kinase inhibitor for FLT3-ITD-positive AML - Leukemia - 201605 - 2016, 30
6) Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML - Leukemia - 201603 - 2016, 30
7) Discovery of a BTK/MNK Dual Inhibitor for Lymphoma and Leukemia - Leukemia - 201601 - 2016, 30
8) Discovery of 4-Methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl) phenyl)-3-((1-nicotinoylpiperidin-4-yl)oxy)benzamide (CHMFL-ABL/KIT-155) as a Novel Highly Potent 4 Type II ABL/KIT Dual Kinase Inhibitor with a Distinct Hinge Binding - J. Med. Chem. - 201701 - 2017, 60
9) Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutants Kinase Inhibitor with a Distinct Binding Mode - J. Med. Chem. - 201704 - 2017, 60
10) Discovery of N(3-((1-Isonicotinoylpiperidin-4-yl)oxy)-4-methylphenyl)-3- (trifluoromethyl)benzamide (CHMFL-KIT-110) as a Selective Potent, and Orally Available Type II cKIT Kinase Inhibitor for Gastrointestinal Stromal Tumors (GISTs) - J. Med. Chem. - 201604 - 2016, 59
11) Discovery of (E)-N1-(3-Fluorophenyl)-N3-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)malonamide (CHMFL-KIT-033) as a Novel c-KIT T670I Mutant Selective Kinase Inhibitor for Gastrointestinal Stromal Tumors (GISTs) - JOURNAL OF MEDICINAL CHEMISTRY - - 0022-2623
12) Discovery of (E)-N1-(3-Fluorophenyl)-N3-(3-(2-(pyridin-2- yl)vinyl)-1H-indazol-6-yl)malonamide (CHMFL-KIT-033) as a Novel c-KIT T670I Mutant Selective Kinase Inhibitor for Gastrointestinal Stromal Tumors (GISTs) - JOURNAL OF MEDICINAL CHEMISTRY - - 0022-2623
13) Discovery of N-(4-(6-Acetamidopyrimidin-4-yloxy)phenyl)-2-(2- (trifluoromethyl)phenyl)acetamide (CHMFL-FLT3-335) as a Potent FMS-like Tyrosine Kinase 3 Internal Tandem Duplication (FLT3-ITD) Mutant Selective Inhibitor for Acute Myeloid Leukemia - JOURNAL OF MEDICINAL CHEMISTRY - - 0022-2623